Ocuphire Pharma Investor Update
RM
34
More Efficient Launch Opportunity for Nyxol in RM
Launch is Poised to be Disruptive, Cost-Effective and Not Payor-Driven
XX
XXXX
Traditional Ophthalmic Launch
Highly competitive markets (e.g., dry eye,
glaucoma, allergy); little differentiation
Launch success takes time given payor
(reimbursement) dependence
Significant prior authorization & step-edits
hurdles with burden to the practices
Lengthy sales cycles and touchpoints due to
chronic use and market access upkeep
Significant product education requirement
Complex distribution channel including
specialty and retail pharmacies
"One product, one indication" commercial
model is inefficient with fixed cost infrastructure
Ocuphire's Nyxol RM Launch
No competition or approved reversal drop →
potential for Nyxol to be the only safe option
Cash pay (no reimbursement barriers)
allowing for quicker adoption
Offering a significant value proposition to
patients and practices
Shortened sales-cycle with acute use
product
No training given dilations routine in
practices
No specialty/retail pharmacy → direct to
physician
"One product, several indications" offers
efficiencies in commercial operations
Ocuphire
PHARMAView entire presentation